Rapid Action Consortium

Frequently Asked Questions

  • Facebook
  • Twitter
  • Linkedin
  • Email

What is the Rapid Action Consortium?

The U.S. Rapid Action Consortium is a collaboration of leading organizations coming together to help companies develop and deploy Rapid Antigen testing for COVID-19 in workplaces across the U.S. to help accelerate the reopening of the economy. 

The U.S. Rapid Action Consortium is modelled off the successful Creative Destruction Lab Rapid Screening Consortium in Canada, of which Genpact is a founding partner. The learnings from this Canadian project are the foundation on which the US consortium is built. 

Why do we need the Consortium?

In addition to being a global health crisis and an economic crisis, COVID-19 is fundamentally an information problem of a size and scale the world has never seen before. As with any complex, global information problem, the solution will require intelligent use of data and technology, and the ability for the right parties to come together to create ecosystems of impact.

With millions of lives impacted and billions of dollars being lost in economic activity each week, a systematic approach to testing will better enable US businesses in creating a safer workplace. Even as vaccine adoption progresses, testing will be a critical part of workforce health and safety for the foreseeable future. 

There is a steep learning curve for everyone - companies, employees, government, citizens, etc. - to deploy cheap rapid tests at scale: screening technologies, supply chain, data management, implementation, etc. We can learn faster by sharing information across companies. 

Who is part of the Consortium?

Three leading organizations have come together to leverage their expertise and reach to bring this to the U.S.:

1. The Creative Destruction Lab RSC - As the founder of the movement in Canada, the Creative Destruction Lab Rapid Screening Consortium (CDL RSC), a non-profit organization dedicated to making rapid testing a part of a safe workplace environment, will be the Thought Partner for the Rapid Action Consortium.

2. Genpact - As a founding member of the CDL RSC, Genpact will be the Operating Partner for the Rapid Action Consortium, leveraging its expertise as a U.S.-based digital transformation company with deep experience in data analytics and process management to help with the organization’s mission.  Genpact’s expertise in leveraging data and technology to solve the most complex business problems will be leveraged to help solve the world’s most complex information problem. 

3. The COVID Collaborative - As the leading national assembly of experts, leaders and institutions coming together to turn the tide on the pandemic, the COVID Collaborative will be a founding partner and advisor to the Rapid Action Consortium. 

Why is this consortium important?

COVID-19 is, at its core, an information problem. 1 in 1,000 asymptomatic people are infected with COVID-19. The ability to effectively and rapidly identify those who are infectious is critical to a healthy and stable environment, yet a ready-to-go, off-the-shelf rapid screening solution does not exist. And even as vaccine adoption progresses, testing will be a critical part of workforce health and safety for some time. 

The ability to test effectively at scale is very much still in its infancy. There is a steep learning curve for everyone - companies, employees, governments, citizens - to deploy low-cost rapid tests at scale: screening technologies, supply chain, data management, implementation, etc. We can learn faster by sharing information across businesses.

Why should my company join if COVID-19 vaccines are already being deployed?

Scientists and experts agree that COVID-19 will not be fully eradicated anytime soon, and Rapid Antigen testing, along with other actions, are essential to public safety and in reopening the U.S. economy.

What will my company be supporting?

The sharing of proven screening protocols and the offer of rapid COVID-19 tests at businesses. Once developed and deployed, our learnings and approaches will be offered as a public good to all organizations, large and small. 

How do Rapid Antigen tests work?

Rapid Antigen tests detect the presence or absence of an antigen unique to a particular virus – in this case COVID-19. They are designed for screening purposes vs. the diagnosis of acute infection, and are faster and less costly than PCR tests, while maintaining a high accuracy rate. Nevertheless, a positive Rapid Antigen test is always followed by a confirmatory PCR test. For more information, visit the CDC site on Antigen Testing

Is being infectious different than being infected?

Yes. While Rapid Antigen tests may not determine whether someone is infected with a low viral load of the coronavirus, they are sensitive in determining whether someone is infectious. This means that rapid tests can be applied at our workplaces as a frontline screening tool to monitor frequently, break chains of transmission, and make places safer. For more information on transmission, visit this section of the CDC’s website

What data will companies collect from employees participating in these tests?

In general, companies usually collect data about the type of tests administered, the time a test was taken, site specific variables, and the results of the screening test. Each company will collect data locally, then selected data will be deidentified, aggregated, and shared with the Consortium. No personally identifiable data is shared with the Consortium. 

Is there a cost to joining the Consortium?

There is no fee to join the Consortium. Each company will be responsible for providing the internal resources needed to be a member of the Consortium. Each will need to fund tests and IT support for their organization. 

Who is on the advisory committee of the Consortium? 

  • Dr. Michael Mina – Harvard School of Public Health
  • Dr. Ajay Agrawal – Creative Destruction Lab Rapid Screening Consortium
  • Dr. Steven Phillips – Covid Collaborative
  • Darren Saumur - Genpact
  • Stacy Simpson - Genpact
  • Dr. Janice Stein – Creative Destruction Lab Rapid Screening Consortium
  • Sonia Sennik - Creative Destruction Lab Rapid Screening Consortium